2013 annual report - hospital de câncer de barretos 2013_cpom.pdf2013 annual report molecular...

Molecular Oncology Research Center - BARRETOS CANCER HOSPITAL1

This annual report describes the Molecular Oncology Research Center (CPOM) from the Barretos Cancer Hospital, and its research activities for the year 2013.

2013 Annual Report

Molecular Oncology Research Center


Index

1) Mission....................................................................................................................................32) Team.......................................................................................................................................43) Research Lines.........................................................................................................................74) Productivity.............................................................................................................................95) Conferences and Congresses................................................................................................176) Science Communication to general public............................................................................267) Supervision of PhD, Master and Initiation to Trainee Fellows..............................................268) Prizes....................................................................................................................................309) Participation in International Networks................................................................................3110) Participation in National Networks.....................................................................................3211) Organization of Conferences and Meetings........................................................................3212) Lectures / Seminars at Conferences and Meetings............................................................3213) Funding...............................................................................................................................3614) Patents................................................................................................................................4115) Jury participation................................................................................................................4216) National and International Collaborations:.........................................................................4417) Molecular Diagnostics Center.............................................................................................4518) Perspectives for 2014.........................................................................................................45

3 Molecular Oncology Research Center – Barretos Cancer Hospital

Introduction

The Molecular Oncology Research Center “Centro de Pesquisa em Oncologia Molecular”

(CPOM) was inaugurated on August 19, 2010, by the former Minister of Health, Dr. José

Temporão. The CPOM is framed at the Institute for Research and Education “Instituto de

Ensino e Pesquisa” (IEP) of Barretos Cancer Hospital, which in conjunction with other

clinical departments of the Hospital, as well as the Department of Clinical Research and Post-

graduation in Oncology, are the basic foundations in developing the future of oncology

medicine - personalized medicine.

The CPOM is installed in the new building of the IEP, with an area of 1,000 m2. The project

design was based on the most modern research centers, emphasizing the convenience of

movement, sharing of technological resources and the supervision of experience professionals.

The complex infrastructure of CPOM counts with state-of-the-art laboratories of cytogenetics,

molecular genetics, and molecular and cellular biology, allowing the development of different

research lines of in the field of molecular oncology.

During 2013, the third year of CPOM, we observed the growing of the projects generated in

the first couple of years, and the increased number of approved grants by Funding Agencies,

as well as the implementation of numerous and varied scientific partnerships. A steady

increased of the number of researchers was also observed during this year.

To evaluate and guide their steps, the CPOM was an External Advisory Board, which consists

of the following members:

- Jorge Reis-Filho (MSKCC, USA)

- Jorge Gomez (NCI, USA)

- Luisa Villa (INCT-CNPq, Brazil)

- Manuel Sobrinho-Simões (IPATIMUP, Portugal)

- Oliver Bogler (MDAnderson, USA)

1) Mission

To promote knowledge and innovation in order to apply molecular oncology in cancer control.

- Knowledge of the causes, biological mechanisms and targets,


- Innovation in detection, diagnostic, treatment and prognosis,

- Application in prevention and assistance to patient.

2) Team

Senior Researcher

Adhemar Longatto-Filho, PhD – Coordinator of Post-graduation

André Lopes Carvalho, MD, PhD – IEP Executive Director

Benedito Mauro Rossi, MD, PhD – External Collaborator

Ismael Dale Cotrim Guerreiro da Silva, MD, PhD – External Collaborator

José Humberto Tavares Guerreiro Fregnani, MD, PhD – IEP Scientific Diretor

Luiz Fernando Lopes, MD, PhD – Pediatric Hospital Coordinator

Rui Manuel Reis, PhD – Molecular Oncology Research Center Coordinator

Visitant Professor

Kari J Syrjanen, MD, PhD – University of Turku, Finland

Junior Researcher

Céline Marques Pinheiro, PhD – External Collaborator, FACISB

Cristovam Scapulatempo-Neto, MD, PhD – Department of Pathology Coordinator

Daniel Onofre Vidal, PhD – Researcher

Denise Peixoto Guimarães, MD, PhD – Departament of Endoscopy

Edenir Inêz Palmero, PhD – Researcher

Eduardo Anselmo Garcia, PhD - External Collaborator, FACISB

Fernanda Scarnato de Rosa, PhD - External Collaborator, UNIFEB

Henrique César Santejo Silveira, PhD – Researcher

Lucas Tadeu Bidinotto, PhD - External Collaborator, FACISB

Márcia Maria Chiquitelli Marques Silveira, PhD – Researcher

Marjori Leiva Camparoto, PhD – Researcher

Olga Martinho, PhD - External Collaborator, ICVS/UMinho

Vinicius de Lima Vazquez MD, PhD – Clinical Diretor.

Post-doc

Adriane Feijó Evangelista, PhD

Ana Carolina Carvalho, PhD

Matias Eliseo Melendez, PhD


Vânia Sanmartino Mariano, PhD

Viviane Silva, PhD

PhD students

Adriana Tarlá Lorenzi

Aline Becker

Lidia Maria Rebolho Batista Arantes

Master students

Camila Martinelli

Carla Aparecida Pinheiro

Flávia Coltri Eguchi

Larisa Kuil

Natalia Campacci

Nathalia Campanella

Paula Roberta Aguiar Pastrez

Taciane Macedo

Vanessa Uzan

Biologists / Bioinformaticians / Technical support

Aline Tansine, PhD

Adriana Cruvinel Carloni (master student)

Alessandra Paulino dos Santos

André Escremim de Paula

André Van Helvoort Lengert

Flávia Escremim de Paula, PhD

Gabriela Carvalho Fernandes (master student)

Gustavo Noriz Berardinelli (PhD student)

Maicon Fernando Zanon da Silva (master student)

Marcela Nunes

Maressa Ferreira Neto, PhD

Raul Torrieri

Renato José da Silva Oliveira (PhD student)

Research Initiation / Trainee


Anna Luiza Silva Almeida Vicente

Cintia Batista de Oliveira

Fernanda Costa Ferreira

Fernanda Cury

Karina Pepineli de Mello

Karla Rodrigues de Assis

Livia Marques dos Santos

Marina Schimidt Carrijo

Manoela Catarina Aguena Souza Ramos

Tereza Victoria de Castilho Niero Simoes

Verônica Crissatti

Weder Pereira de Menezes

Administrative/IT/Comercial

Ednise Woyciechowski –IEP manager

Tamiris Regina Ribeiro de Moraes – Administrative Assistant - CPOM

Marcella Marchioretto – Financial Analyst - EPIT

Osmar Alves – IT support

Raphael Alves Ramos Assunção – Administrative Assistant - Molecular Diagnostic

Amanda Costa – Administrative Assistant - EPIT

Paulo Ferreira – Marketing and Comercial


3) Research Lines

- Cellular Signaling

One of the hallmarks of cancers is the oncogenic upregulation of the signaling cascades that

govern the transduction of extracellular growth factors to cellular nuclear response. Among

these plethora of players, receptor tyrosine kinases (RTKs) and intracellular MAPK,

PI3KCA/AKT and JAK/STAT pathways, have a crucial impact in cancer development,

behavior and currently, there is also an attractive therapeutic target. Our group is focused in

evaluate the major genetic alterations that disrupt these cellular circuits, and understand their

impact on patient prognosis and therapeutic response. Additionally, using tumor cell line and

primary culture models we intend to understand their function and biological impact on

cancer.

- Biomarkers

We now know that cancer is a disease of the genome and this new vision has introduced a

new paradigm. In this scenario, the genome of the cancer can be more objectively in the

stratification of patients with cancer, leading to the emerging personalized medicine in

oncology. In order to achieve this aim, it is necessary to identify from the myriad of cancer

genomic changes, which ones have a clinical value - biomarkers. The diagnosis based on the

genome, it should present a high sensitivity and specificity, and detection of these biomarkers

should be possible not only in tumor tissue, but also extended to other body fluids such as

plasma, serum, urine, saliva, strokes cavity, allowing so early detection and the ability to

monitor tumor development. With a huge bank of tissues and fluids of cancer patients in

Barretos Hospital of Cancer (CrioBio) and a detailed medical history, our group intends to

validate potential biomarkers known in the Brazilian population, as well as identify new

biomarkers.

- Functional Genomics of Cancer

The genomic science aims to understand how genes and genetic information is organized

within the genome (structural genomics) and how the organization determines its function

(functional genomics). The functional genomics applied to cancer aims to evaluate

systematically and simultaneously, the expression of genes (mRNA), microRNAs or proteins

to a better understanding of the molecular genetic basis governing the process of

carcinogenesis. Our research group intends to use the functional genomics resources for

transcriptional signatures mRNA and microRNAs expression in order to point out potential

molecular biomarkers of tumor progression. Additionally, using tumor cell line we can

validate the miRNA-mRNA interactions through functional tests using silencing of miRNAs

(using anti-miRNAs or anti-MIRs) and thus assess the impact of these new biomarkers in the

progression cancer.


- Environmental factors and Cancer

The exposure to different types of environmental factors such as: food, occupational

conditions, medications, hormones, radiation, viruses, bacteria, chemical agents, air pollution

and water are intrinsically linked to the occurrence of cancer in exposed populations. The

determination of the potential cancer risk in the exposure to environmental factors can

contribute to public policies and preventive measures. Therefore, our research group aims to

assess populations exposed to chemical or environmental factors using genetic biomarkers.

Considering the susceptibility of each individual to metabolize carcinogenic agents, we intend

to reveal the molecular mechanisms involved in the resistance to these compounds,

polymorphisms, gene-environment interactions and its implications in carcinogenesis.

- Hereditary Cancer

Several cancers developed in higher than normal frequencies may be related to inherited

genetic alterations, present in predisposed families. Around 10% of most cancer types are due

to the presence of germline mutations, leading to an increased lifetime cancer risk. The

recognition of a hereditary cancer-affected individual is crucial for the identification of other

at-risk family members and their inclusion in cancer risk reduction strategies. The focus of

our research group is to prematurely identify, characterize and analyze, clinically and

molecularly, these at-risk individuals. Genetic modifiers that may contribute to an increased

cancer development risk, such as genetic polymorphisms, rearrangements, copy number

variations are also part of our research work.

- Epigenetics

Epigenetics are related to reversible events that do not produce modification in the genomic

DNA sequence, but rather alters its phenotype, influencing mechanisms related to gene

expression. Methylation is the most common epigenetic event, being a very important

biologic process involved in gene silencing. The study of hypermethylation can give vital

information on the understanding of carcinogenesis, as well as the evaluation of its pattern can

be used as a biomarker for diagnosis, treatment planning and prognosis of an individual.

- Pediatric Tumor Biology

Although considered rare, childhood cancer is the leading cause of disease-related mortality in

children. Cancer in the childhood often is more devastating and aggressive than their

counterparts in adults. Despite the progress in cure rates and survival improvement achieved

in the last Decades, there is a group of tumors that still do not respond to any available

standard treatment. Our goal is to apply the knowledge and tools of molecular biology to

clarify and understand the biology and pathogenesis of pediatric tumors, in order to identify


potential biological markers that may support diagnosis and/or indicate prognosis of pediatric

patients. As well, we are looking for the altered pathways/genes that can be targets for new

therapy strategies.

4) Productivity

4.1) Books or Book Chapters

1. de Mello R, Araújo A, Reis RM, Hespanhol V. The role of genetic polymorphisms in the

angiogenesis pathway and non-small cell lung cancer tumor behavior: implications in risk

assessment and clinical outcome. In: Mehta JL, Dhalla NS. (Org.). Biochemical Basis and

Therapeutic Implications of Angiogenesis, Advances in Biochemistry in Health and Disease,

381-403, 2013.

2. Fregnani JH. Future Strategies for Cervical Cancer Prevention in Developing Countries:

HPV vaccine and Its Implementation around the World. In: Breast and Gynecological

Cancers. An Integrated Approach for Screening and Early Diagnosis in Developing

Countries.1st ed.New York: Springer, 320-329, 2013.

3. Branca M, Longatto-Filho A. A Manual for Cervical Cancer Screening and Control:

Principles, Practice and New Perspectives NOVA Publishers Publishers, New York, 2013.

4. Paixao Becker A, Scapulatempo-Neto C, Neder L, Chimelli L, Reis RM. Pilocytic

Astrocytoma: Anatomic, pathological and molecular aspects. Clinical Management and

Evolving Novel Therapeutic Strategies for Patients with Brain Tumors, InTech, p.127-143,

2013.

5. Scapulatempo-Neto C, Costa H. Câncer de esôfago. Manual De Padronização de Laudos

Anátomo Patológicos, 4 edição, Editora Manole, 602-615, 2013.

4.2) Publications in International Journals

1. Abrahão-Machado LF, Jacome AA, Wohnrath DR, Dos Santos JS, Carneseca EC, Fregnani

JH, Scapulatempo-Neto C. HER2 in gastric cancer: Comparative analysis of three different

antibodies using whole-tissue sections and tissue microarrays. World Journal of

Gastroenterology. 6438-46, 2013. IF: 2,594


2. Afonso J, Longatto-Filho A, Martinho O, Lobo F, Amaro T, Reis RM, Santos LL. RKIP

downregulation associates with poor prognosis in bladder cancer patients. Virchows Archiv.

445-53, 2013. IF: 2.676

3. Amorim R, Martins S, Longatto-Filho,A, Preto A, Baltazar F. Exploiting monocarboxylate

transporters as new molecular targets for colorectal carcinoma therapy. BMC Proceedings.

7(2), 60, 2013. IF: NA

4. Azevedo MM, Pinheiro C, Yaphe J, Baltazar F (2013). Assessing the Impact of a School

Intervention to Promote Students’ Knowledge and Practices on Correct Antibiotic Use.

International Journal Environmental Research Public Health. 2920-31. IF: 1.998

5. Azevedo MM, Miranda IM, Ricardo E, Silva AP, Pinheiro C, Pina-Vaz C, Rodrigues AG

(2013). Input of University Júnior 2012 to Science Education: a cross study among

Portuguese students. Education Research Journal 50- 58, 2013. IF: NA

6. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L,

Syrjänen K. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and

dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum

biomarkers. Anticancer Research. 4595-602, 2013. IF: 1.713

7. Campanella NC, de Oliveira AT, Scapulatempo-Neto C, Peixoto-Guimarães D, Reis RM.

Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs). Recent

Patents on Anti-Cancer Drug Discovery. 288-297, 2013. IF: 2.700

8. Campos M, DE Campos SG, Ribeiro GG, Eguchi FC, Silva SR, DE Oliveira CZ, DA Costa

AM, Curcelli EC, Nunes MC, Penna V, Longatto-Filho A. Ki-67 and CD100

immunohistochemical expression is associated with local recurrence and poor prognosis in

soft tissue sarcomas, respectively. Oncology Letters. 1527-1535, 2013. IF: 0.237

9. Carneseca EC, Mauad EC, Araújo MA, Dalbo RM, Longatto-Filho A, Vazquez VL. An

analysis of cancer survival at a single institution in Brazil over a 10-year period. BMC

Research Notes, 141, 2013. IF: NA

10. Cássio Zequi SD, Fregnani JH, Favaretto RL, Costa WH, Madeira Campos RS, Fonseca

FP, Guimaraes GC, Soares FA, da Cunha IW, Lopes A. The impact of immunohistochemical

expression of nitric oxide synthases on clinical and pathological features of renal cell

carcinoma. World Journal of Urology. 1197-203, 2013. IF: 2.888

11. Carvalho TG, De Carvalho AC, Maia DC, Ogawa JK, Carvalho AL, Vettore AL. Search

for mutations in signaling pathways in head and neck squamous cell carcinoma. Oncology

Reports. 334-40, 2013. IF: 2.297


12. Colleoni JL, Rodrigues LM, Junior GS, Scapulatempo C, Abreu LC, Valenti VE, Fujiki E,

Camargo RC, Oliveira FR, Alves MT, Cohen M. Immunohistochemical analysis of

mechanoreceptors in the human posterior cruciate ligament: association with aging male.

Aging Male. 73-8, 2013. IF: 1.711

13. de Castro Mattos JS, Mauad EC, Syrjänen K, Longatto-Filho A, Haikel RL, Da Costa

Vieira RA, Silva TB, De Barros N. The impact of breast cancer screening among younger

women in the Barretos Region, Brazil. Anticancer Research. 2651-5, 2013. IF: 1.713

14. de Mello RA, Ferreira M, Pires FS, Costa S, Luis M, Pozza DH, Cunha J, Oliveira P,

Hespanhol V, Reis RM. The impact of polymorphic variations in the 5p15, 6p12, 6p21 and

15q25 loci on the risk and prognosis of Portuguese patients with non-small cell lung cancer.

PlosOne. 2013. IF: 3.730

15. de Mello RA, Araújo A, Hespanhol V, Reis RM. Loci identified through genome-wide

association studies and lung cancer risk: is there anything more? Sao Paulo Medical Journal.

135-6, 2013. IF: NA

16. de Oliveira CM, Fregnani JH, Carvalho JP, Longatto-Filho A, Levi JE. Human

papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC

Cancer. 357, 2013. IF: 3.333

17. Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira MS; Brazilian

Collaborative Study Group of Infant Acute Leukaemia. The distribution of MLL breakpoints

correlates with outcome in infant acute leukaemia. British Journal of Haematology. 224-36,

2013. IF: 4.942

18. Filassi JR, Zonta MA, Trinconi A, Calvagno D, Velame de Oliveira F, Ricci MD, Baracat

E, Longatto-Filho A. Can breast nipple fluid collected with automated aspiration and

preserved in based-liquid solution improve the cytological samples? Acta Cytologica. 276-80,

2013. IF: 0.693

19. Fregnani JH, Carvalho AL, Eluf-Neto J, Ribeiro Kde C, Kuil Lde M, da Silva TA,

Rodrigues SL, Mauad EC, Longatto-Filho A, Villa LL. A school-based human papillomavirus

vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One.

62647, 2013. IF: 3.730

20. Fregnani JH, Scapulatempo-Neto C, Haikel RL Jr, Saccheto T, Campacci N, Mauad EC,

Longatto-Filho A. Could alarmingly high rates of negative diagnoses in remote rural areas be

minimized with liquid-based cytology? Preliminary results from the RODEO study team.

Acta Cytologica. 69-74, 2013. IF: 0.693

21. Garcia EA, Simões K, Wakamatsu A, Cirqueira SC, Alves VAF, Longatto-Filho, A,


Camargo RS. Pro and Anti-Angiogenic Vascular Endothelial Growth Factors Expression in

Benign and Malignant Thyroid Lesions. Journal of Thyroid Disorders & Therapy, v. 2, 1-6,

2013. IF: NA

22. Giacomazzi J, Koehler-Santos P, Palmero EI, Graudenz MS, Rivero LF, Lima E, Pütten

AC, Hainaut P, Camey SA, Michelli RD, Neto CS, Fitarelli-Kiehl M, Geyer G, Meurer L,

Geiger A, Azevedo MB, da Silva VD, Ashton-Prolla P. A TP53 founder mutation, p.R337H,

is associated with phyllodes breast tumors in Brazil. Virchows Archiv. 17-22, 2013. IF: 2.676

23. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis

JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D,

Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F,

Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R,

Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A,

de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho AL, Gil CF, Sternberg C,

Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R,

Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I,

Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F,

Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Planning cancer control in

Latin America and the Caribbean. Lancet Oncology. 391-436, 2013. IF: 25.117

24. Jácome AA, Wohnrath DR, Scapulatempo Neto C, Fregnani JH, Quinto AL, Oliveira AT,

Vazquez VL, Fava G, Martinez EZ, Santos JS. Effect of adjuvant chemoradiotherapy on

overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer.

233-238, 2013. IF: 3.989

25. Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS,

Nunes JS, Martinez EZ, Santos JS. Prognostic value of epidermal growth factor receptors in

gastric cancer. A survival analysis by Weibull model incorporationg long-term survivors.

Gastric Cancer. 2013. IF: 3.989

26. Liberman PH, Schultz C, Goffi-Gomez MV, Lopes LF. Speech recognition and frequency

of hearing loss in patients treated for cancer in childhood. Pediatric Blood Cancer. 1709-13,

2013. IF: 2.353

27. Linhares P, Carvalho BM, Figueiredo R, Reis RM, Vaz R. Early Pseudo-progression

Following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.

Journal of Oncology. 2013. IF: NA


28. Linhares P, Martinho O, Carvalho B, Castro L, Lopes JM, Vaz R, Reis RM. Analysis of a

synchronous gliosarcoma and meningioma with long survival: A case report and review of the

literature. Surgical Neurology International, 2013. IF: NA

29. Lorenzi AT, Fregnani JH, Possati-Resende JC, Neto CS, Villa LL, Longatto-Filho A.

Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test.

Gynecologic Oncology. 131-4, 2013. IF: 3.929

30. Koskela HM, Syrjänen K, Korkeila EA. Disease outcome of patients with pancreatic

cancer in a cohort treatedoutside clinical trials. Anticancer Research. 5491-4, 2013. FI: 1.713

31. Macedo C, Evangelista AF, Marques MMC, Octacilio-Silva S, Donadi EA, Sakamoto-

Hojo ET, Passos GAS. Autoimmune regulator (Aire) controls the expression of microRNAs

in medullary thymic epithelial cells. Immunobiology. 554-60, 2013. IF: 2.814

32. Martinho O, Silva-Oliveira R, Miranda-Gonçalves V, Clara C, Almeida JR, Carvalho AL,

Barata JT, Reis RM. In vitro and in vivo analysis of RTKs inhibitors efficacy and

identification of its novel targets in glioblastomas. Translational Oncology. 187-96, 2013. IF:

2.943

33. Martinho O, Simões K, Longatto-Filho A, Jacob CE, Zilberstein B, Bresciani C, Gama-

Rodrigues J, Cecconello I, Alves V, Reis RM. Absence of RKIP expression is an independent

prognostic biomarker for gastric cancer patients. Oncology Reports. 690-6, 2013. IF: 2.297

34. Martinho O, Pinto F, Granja S, Miranda-Gonçalves V, Moreira MAR, Ribeiro LJF, di

Loreto C, Rosner MR, Longatto-Filho A, Reis RM. RKIP inhibition in cervical cancer is

associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS

One. 8, 2013. IF: 3.730

35. Martino A, Sainz J, Reis RM, Moreno V, Buda G, Lesueur F, Marques H, García-Sanz R,

Ríos R, Stein A, Dumontet C, Gemignani F, Rossi AM, Landi S, Jurado M, Petrini M,

Jamroziak K, Campa D, Canzian F. Polymorphisms in regulators of xenobiotic transport and

metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in

the context of IMMEnSE consortium. Journal of Human Genetics. 155-9, 2013. IF: 2.365

36. Martins S, Garcia EA, Luz MA, Pardal F, Rodrigues M, Longatto-Filho A.

Clinicopathological Correlation and Prognostic Significance of VEGF-A, VEGF-C, VEGFR-

2 and VEGFR-3 Expression in Colorectal Cancer. Cancer Genomics Proteomics. 55-67, 2013.

IF: NA

37. Martins S, Amorim R, Reis RM, Pinheiro C, Rodrigues M, Baltazar F, Longatto-Filho A.

A Hospital Based Cohort Study of Colorectal Cancer Cases Treated at Braga Hospital,

Northern Portugal. Journal of Gastrointestinal & Digestive System. 146, 2013. IF: NA


38. Miranda-Gonçalves V, Honavar M, Martinho O, Pires MM, Pinheiro C, Cordeiro M,

Bebiano G, Costa P, Palmeirim I, Reis RM, Baltazar F. Monocarboxylate transporters (MCTs)

in gliomas: expression and exploitation as therapeutic targets. Neuro-Oncology. 172-88, 2013.

IF: 6.180

39. Moniz S, Martinho O, Pinto F, Sousa B, Loureiro C, Oliveira MJ, Moita LF, Honavar M,

Pinheiro C, Pires M, Lopes JM, Jones C , Costello JF, Paredes J, Reis RM, Jordan P. Loss of

WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-

mediated tumour cell invasiveness. Human Molecular Genetics. 84-95, 2013. IF: 7.692

40. Morais-Santos F, Miranda-Gonçalves V, Pinheiro S, Vieira AF, Paredes J, Schmitt FC,

Baltazar F, Pinheiro C (2013). Differential sensitivities to lactate transport inhibitors of breast

cancer cell lines. Endocrine-Related Cancer. 27-38, 2013. IF: 5.261

41. Oliveira RDR, Fontana V, Junta CM , Marques MM, Macedo C, Rassi DM, Passos GAS,

Donadi EA, Louzada-Jr P. Differential gene expression profiles Maio differentiate responder

and non-responder rheumatoid arthritis patients for methotrexate monotherapy and

methotrexate plus TNF-blocker combined therapy. The Journal of Rheumatology. 1524-32,

2013. IF: 3.690

42. Osório NS, Rodrigues F, Garcia EA, Costa MJ. Drawings as snapshots of student cellular

anatomy understanding. Medical Education, 1120-1121, 2013. IF: 3.546

43. Paugh BS, Zhu X, Qu X, Endersby R, Zhang J, Bax DA, Carvalho D, Reis RM, Onar-

Thomas A, Broniscer A, Wetmore C, Jones C, Zhang J, Ellison DW, Baker SJ. Novel

Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas. Cancer Research. 6219-

6229, 2013. IF: 8.650

44. Polli CD, Toledo KA, Franco LH, Mariano VS, Oliveira LL, Bernardes ES, Roque-

Barreira MC, Pereira-da-Silva G. Monocyte Migration Driven by Galectin-3 Occurs through

Distinct Mechanisms Involving Selective Interactions with the Extracellular Matrix. ISRN

Inflammation. 28, 2013. IF: NA

45. Rettori MM, de Carvalho AC, Bomfim Longo AL, de Oliveira CZ, Kowalski LP,

Carvalho AL, Vettore AL. Prognostic significance of TIMP3 hypermethylation in post-

treatment salivary rinse from head and neck squamous cell carcinoma patients.

Carcinogenesis. 20-7, 2013. IF: 5.635

46. Rettori MM, de Carvalho AC, Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL,

Vettore AL. TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased

incidence of second primary tumors. Journal of Translational Medicine. 316, 2013. IF: 3.46

47. Roncaglia MT, Fregnani JH, Tacla M, DE Campos SG, Caiaffa HH, Ab'saber A, DA


Motta EV, Alves VA, Baracat EC, Longatto Filho A. Characterization of p16 and E6 HPV-

related proteins in uterine cervix high-grade lesions of patients treated by conization with

large loop excision. Oncology Letters. 63-68, 2013. IF: 0.237

48. Scapulatempo C, Fregnani JH, Campacci N, Possati-Resende JC, Longatto-Filho A. The

significance of augmented high-grade squamous intraepithelial lesion detection on pap test

examination: partial results from the RODEO study team. Acta Cytologica. 489-94, 2013. IF:

0.698

49. Silva AG, Maschietto M, Vidal DO, Peliçario LM, Velloso ED, Lopes LF, Krepischi AC,

Rosenberg C. Array-CGH as an adjuvant tool in cytogenetic diagnosis of pediatric MDS and

JMML. Medical Oncology. 734, 2013. IF: 2.147

50. Silva TB, Mauad EC, Carvalho AL, Jacobs LA, Shulman LN. Difficulties in

implementing an organized screening program for breast cancer in Brazil with emphasis on

diagnostic methods. Rural Remote Health. 2013. IF: 0.979

51. Silveira HCS, Carrijo MS, Seidel EH, Scapulatempo Neto C, Longatto Filho A, Carvalho

AL, Reis RM, Saldiva PH. Emissions generated by sugarcane burning promote genotoxicity

in rural workers: a case study in Barretos, Brazil. Environmental Health. 87, 2013. IF: 2.714

52. Sonaglio V, de Carvalho AC, Toledo SRC, Salinas-Souza C, Carvalho AL, Petrilli AS, de

Camargo B, Vettore AL. Aberrant DNA methylation of ESR1 and p14ARF genes could be

useful as prognostic indicators in osteosarcoma. OncoTargets and Therapy. 713-23, 2013. IF:

2.073

53. Stein MD, Fregnani JH, Scapulatempo C, Mafra A, Campacci N, Longatto-Filho A;

RODEO Study Team From Barretos Cancer Hospital. Performance and Reproducibility of

Gynecologic Cytology Interpretation Using the FocalPoint System: Results of the RODEO

Study Team. American Journal of Clinical Pathology. 567-71, 2013. IF: 2.88

54. Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, Pedrosa. J.

Phage Therapy Is Effective against Infection by Mycobacterium ulcerans in a Murine Footpad

Model. PLoS Neglected Tropical Diseases. 2183, 2013. IF: 4.569

55. Valente V, Serafim B R, Oliveira C L, Adorni S F, Torrieri R, Tirapelli C P D, Espreafico

M E, Oba-Shinlo M S, Marie N K S, Paçó-Larson L M, Carloti Jr. G C. Modulation of

HJURP (Holliday Junction-Recognizing Protein) Levels Is Correlated with Glioblastoma

Cells Survival. Plos One 25, 2013. IF: 3.730

56. Vecchiatti SM, Guzzo ML, Caldini EG, Bisi H, Longatto-Filho A, Lin CJ. Iodine

increases and predicts incidence of thyroiditis in NOD mice: Histopathological and

ultrastructural study. Experimental and Therapeutic Medicine. 603-607, 2013. IF: 0.344


57. Viana RC, Scapulatempo-Neto C, Kerr LM, Palmero EI, Marques MMC, Colacoiavo T,

Queiroz Junior AF, Carvalho AL, Siqueira SAC. The interference of cold isquemia time in

the quality of total RNA from frozen tumor samples. Cell & Tissue Banking. 167-73, 2013. IF:

1.171

58. Vidal DO, Marques MMC, Lopes LF, Reis RM. The Role of miRNAs in

Medulloblastoma. Pediatric Hematology and Oncology. 367-78, 2013. IF: 0.891

59. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R,

Prazeres H, Lima L, Melo M, Rocha A, Preto A, Castro P, Castro P, Pardal F, Lopes JM, Lara

Santos L, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P.

Frequency of TERT promoter mutations in human cancers. Nature Communications. 26, 2013.

IF: 10.015

60. Wang SJ, Patel SG, Shah JP, Goldstein DP, Irish JC, Carvalho AL, Kowalski LP,

Lockhart JL, Holland JM, Gross ND. An Oral Cavity Carcinoma Nomogram to Predict

Benefit of Adjuvant Radiotherapy. JAMA Otolaryngol Head Neck Surgery. 1-6, 2013. IF:

1.63

4.3) Publications in Brazilian Journals

1. Abud J, Izetti PR, Moreira MA, M, Achatz MIW, Vargas FR, Palmero EI, Cossio SL,

Prolla JC, Ashton PP. Study Group on Hereditary Breast and Colorectal Cancer. CHEK2

1100DELC germline mutation: a frequency study in hereditary breast and colon cancer

Brazilian families. Arquivos de Gastroenterologia. 273-278, 2013. IF: 0.0238

2. Heinke T, Espiríto Santo KS, Longatto Filho A, Stavale JN. Vascular endothelial growth

factor and KIT expression in relation with microvascular density and tumor grade in

supratentorial astrocytic tumors. Acta Cirurgica Brasileira. 48-54, 2013. IF: 0.626

3. Passos-Filho O, Cangussu HC, Lopes RH, Oliveira AT, Vazquez VL, Galvão CN.

Síndrome de Boerhaave: relato de caso. Revista do Colégio Brasileiro de Cirurgiões. 83-84,

2013. IF: 0.0317

4. Velloso ED, Chauffaille ML, Peliçario LM, Tanizawa RS, Toledo SR, Gaiolla

RD, Lopes LF. Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases:

challenges and difficulties in a large and emerging country. Brazilian Journal of Medical

Biological Research. 85-90, 2013. IF: 1.139.


5) Conferences and Congresses

5.1) Oral Communications

1. Berardinelli GN, Souza NCN, Scapulatempo-Neto C, Melanni R, Reis RM. Mutational

profile of Colorectal Cancer Patients: Implication in Anti-EGFR Therapies. III Simpósio

em Oncologia Translacional do Hospital de Câncer de Barretos. August 2013, Barretos,

Brazil.

2. Bidinotto LT, MacKay A, Caravina G, Becker A, Viana-Pereira M, Clara C, Jones C, Reis

RM. Profile of genomic alterations of gliomas. XVI Jornada de Patologia do

A.C.Camargo Cancer Center / VI Encontro Internacional de Patologia Investigativa. 7-10,

2013. São Paulo, Brazil.

3. Campacci N, Lima JO, Ramadan L, Michelli R, Viana DV, Mauad EC, Haikel JRR, Rossi,

BM, Palmero EI. Identification of at-risk families for hereditary colorectal cancer through

a Brazilian Cancer Prevention Network in a population-based sample. In: International

Society for Gastrointestinal Hereditary Tumours - 5th Biennial Meeting, 2013, Cairns,

Australia.

4. de Paula AE, Mendes DRP, Fernandes GC, Berardineli GN, Reis RM, Oliveira JC, Viana

DV, Andrade CEMC, Scapulatempo-Neto C, Palmero EI. Caracterização Molecular de

Famílias em Risco para Câncer Colorretal Hereditário – Importância da realização do

Teste Genético. XXV Congresso Brasileiro de Genética Médica. 11-15, 2013.

Florianópolis, Brazil.

5. de Paula AE, Mendes DRP, Fernandes GC, Legnaro CC, Michelli R, Reis RM, Viana DV,

Andrade CEMC, Palmero EI. Caracterização molecular dos genes BRCA1 e BRCA2 em

famílias com Risco de Câncer de Mama e Ovário Hereditário. XXV Congresso Brasileiro

de Genética Médica. 11-15, 2013. Florianópolis, Brazil.

6. Guimarães DP, Yamane L, Scapulatempo-Neto C, Alvarenga L, Cunha T, Almodova E,

Fava G, Reis RM. Caracterização Endoscópica de Adenomas Serrilhados Sésseis. XII

Semana Brasileira do Aparelho Digestivo. 24-27 November de 2013. Goiânia, Brazil.

7. Lacerda CF, Carloni AC, Scapulatempo-Neto C, Crema E, de Arruda Henry M, Rodrigues

MA, de Oliveira AT, Guimaraes DP, Reis RM. TP53 Gene Mutations in Squamous Cells

Carcinoma of the Esophagus Associated with Chagasic Megaesophagus. Global

Academic Program Meeting, 2013. Houston, USA.

8. Oliveira-Silva RJ, Martinho O, Berardinelli GN, Viana L, Carvalho AL, Reis RM. The

importance of molecular characterization of head and neck cancer cell lines for the

http://lattes.cnpq.br/5051370091705511



prediction of anti-EGFR therapies resistance. III Simpósio em Oncologia Translacional do

Hospital de Câncer de Barretos. 29-30 August de 2013, Barretos, Brazil.

9. Silva-Correia J, Pereira H, Yan LP, Miranda-Gonçalves V, Espregueira-Mendes J,

Oliveira AL, Reis RM, Oliveira JM, Reis RL. Development of Anatomical

Silk/Methacrylated Gellan Gum Scaffolds for Controlling Segmental Vascularization in

Meniscus Tissue Regeneration – TERMIS-EU 2013. Istanbul, Turkey.

10. Silva-Correia J, Pereira H, Yan L-P, Miranda-Gonçalves V, Oliveira AL, Oliveira JM,

Reis RM, Espregueira-Mendes J, Reis RL. Novel Silk-based Scaffolds for Meniscus

Tissue Engineering: The Relevance of Controlling Segmental Vascularization by

Methacrylated Gellan gum Hydrogels – 14th EFORT Congress, 2013. Istanbul, Turkey.

11. Zanon MF, Almeida GC, Matsushita MM, Reis RM, Squire JA, Camparotto ML.

Evaluation of 1p/19q codeletion using FISH analysys in pure and mixed oligodendroglial

tumors at the routine pathology of the Barretos Cancer Hospital-SP, Brazil. 3ª Reunião

Brasileira de Citogenética e IV Simpósio Latino-Americano de Citogenética e Evolução.

26- 29 may 2013. Guarujá, SP, Brazil.

5.2) Posters

1. Almeida M, Portela C, Nabiço R, Ferreira A, Pardal F, Costa S, Ferreira M, Costa P,

Viana-Pereira M, Reis RM. Association of ESR1 polymorphisms with tamoxifen response in

women with estrogen receptor-positive breast cancer. IMPAKT Breast Cancer Conference,

May 2013. Brussels, Belgian.

2. Andrade C, Palmero EI, Viana DV, Michelli R, Fregnani JH. Criteria to screening

endometrial cancer for Lynch Syndrome in a Public Health System. In: 2013 SGO Annual

Meeting on Women s Cancer. 2013, Flórida, USA.

3. Becker A, Bidinotto L, Mackay A, Clara C, Scapulatempo-Neto C, Jones C, Reis RM.

Avaliação de alterações cromossomicas em astrocitomas pilocíticos através da técnica de

array-CGH: Estudo piloto de 4 pacientes do HCB. XXIX Congresso Brasileiro de Patologia.

13-16 November de 2013, Florianópolis, Brazil.

4. Becker A, Clara C, Scapulatempo-Neto C, Reis RM. Caracetrização clinicoepidemiológica

e construção de TMA de uma série de astrocitomas pilocíticos do HCB. XXIX Congresso

Brasileiro de Patologia. November de 2013, Florianópolis, Brazil.

5. Berardinelli GN, Scapulatempo Neto C, Campanella NC, Melani A, Guimaraes DP, Lima

JP, Reis RM. Study of microsatellite instability (MSI) and mutations of MSI-target genes in


large cohort of Brazilian colorectal cancer patients. Global Academic Program Meeting. April

2003, Houston, USA.

6. Bezerra F, Cunha M, Miranda-Gonçalves V, Pinheiro C, Baltazar F. Monocarboxylate

transporters as mediators in tumor-endothelial cell crosstalk. XXII Porto Cancer Meeting.

2013, Porto, Portugal.

7. Campacci N, de Lima JO, Rissatti V, de Toledo EMP, Ramadan L, Palmero EI. O uso de

uma ferramenta de baixo custo para rastreamento de Câncer Hereditário. XXV Congresso

Brasileiro de Genética Médica. Jun 2013. Florianópolis, Brazil.

8. Campanella NC, Scapulatempo-Neto C, de Oliveira AT, Guimarães DP, Reis RM. Study of

microsatellite instability and potential target genes in GISTs. Translating Molecular Biology

into Cancer Treatment. SPSAS – São Paulo School of Advanced Sciences, Advances in

Molecular Oncology. February 2013. São Paulo, Brazil.

9. Campanella NC, Scapulatempo-Neto C, de Oliveira AT, Guimarães DP, Reis RM.

Mutações na região promotora da telomerase reverse transcriptase (TERT) ocorrem em uma

parcela dos GISTs. V Encontro Científico do Hospital de câncer de Barretos. 13-14 Decembre

2013. Barretos, São Paulo, Brazil.

10. Camparotto ML, Castro NS, Gonçalves IZ, Squire JA. Impact of cytogenetic for

evaluation of different diagnostic approach in acute lekemia: a case report. 3º Reunião

Brasileira de Citogenética. May 2013. Águas, Guarujá, São Paulo, Brazil.

11. Carloni AC, Oliveira RJS, Clara C, Camparotto ML, Squire JA, Reis RM. Cytogenetic

and molecular characterization of gliomas primary culture. Translating Molecular Biology

into Cancer Treatment. SPSAS – São Paulo School of Advanced Sciences, Advances in

Molecular Oncology. February 2013. São Paulo, Brazil.

12. Carloni AC, Oliveira R, Bidinotto L, Clara C, Almeida GC, Camparotto ML, Squire JA,

Reis RM. Establishment and cytogentic and molecular characterization of glioblastomas

primary cultures. III Simpósio em Oncologia Translacional do Hospital de Câncer de Barretos.

29-30 de August 2013. Barretos, Brazil.

13. Carvalho Al, Penna V, Pinheiro C A, Reis RM, Squire J, Camparoto ML. Centrosome

clustering in primary sarcomas cultures and its association with malignant behavior in tumor”.

III Simpósio Internacional de Oncologia Translacional do Hospital de Câncer de Barretos. 29-

30 de August 2013. Barretos, Brazil.

14. Carvalho D, Mackay A, Burford A, Chen LBL, Kozarewa I, Lord C, Ashworth A, Reis

RM, Jones C. Integrated whole genome and RNA sequencing identifies novel expressed

fusion transcripts in paediatric high grade glioma. May 2013. Fort Lauderdale, Flórida, USA.


15. Costa A, Oliveira MJ, Martinho O, Pinto F, Jordan P, Reis RM. WNK2 as a modulator of

MMP-2 and MMP-9 expression and activity in Gliomas. VI Congresso Nacional da

Associação Portuguesa de Neuro-Oncologia. 15-16 November 2013. Almada, Portugal.

16. Couto E, Portela C, Almeida M, Nabiço R, Ferreira M, Costa S, Costa P, Viana-Pereira M,

Reis RM. Association of SMAD7 single nucleotide polymorphisms with risk and prognosis of

colorectal cancer in a Portuguese population. ESMO 15th World Congress on Gastrointestinal

Cancer. July de 2013. Barcelona, Spain.

17. Cury FP, Ramos MC, Silveira HC. Assessment of micronuclei frequency in civil

construction workers. III Simposio em Oncologia Translacional do Hospital de Câncer de

Barretos. 29-30 August de 2013, Barretos, Brazil.

18. Cury FP, Ramos MC, Silveira HC. Assessment of micronuclei frequency in civil

construction workers. 59º Congresso Brasileiro de Genética, 2013. 16-19 September 2013.

Águas de Lindóia, Brazil.

19. Cury FP, Ramos MC, Scapulatempo-Neto C, Silveira HC. Assessment of genotoxic

damages in civil construction workers using micronucleus assay. V Encontro Científico do

Hospital de Câncer de Barretos, 2013. July 2013, Barretos, Brazil.

20. de Carvalho AC, Maia DCC, Carvalho AL, Scapulatempo-Neto C, Vettore AL. High

accuracy of microRNAs expression in the detection of lymph node metastasis in patients with

oral squamous cell carcinomas. AACR 104th Annual Meeting 2013. 2013, Washington, USA.

21. de Carvalho AC, Maia DCC, Carvalho AL, Scapulatempo-Neto C, Vettore AL.

Concordance of pathologic examination and qRT-PCR for microRNA expression in lymph

nodes from oral squamous cell carcinoma patients. 4th World Congress of the International

Academy of Oral Oncology, 2013. Greece.

22. Evangelista AF, Macedo T, Oliveira RJS, Marques MMC. MicroRNA-mRNA Networks

for Identification of Biomarkers for Breast Cancer. III Simpósio em Oncologia Translacional

do Hospital de Câncer de Barretos. 29-30 August de 2013, Barretos, Brazil.

23. Evangelista AF, Macedo T; Oliveira RJS, Marques MMC. MicroRNA-mRNA networks

of identification of biomarkers for breast cancer. International Congress of Markers in

Cancer.7–9 de November de 2013. Brussels, Belgian.

24. Evangelista AF, Macedo T; Oliveira RJS, Marques MMC. Integrative analysis of

microRNAs:mRNA expression for breast cancer biomarker discovery. SELECTBIO

Exosomes and Circulating Biomarkers Summit. 12-13September 2013. San Diego, California,

USA.


25. Fernandes GC, Fonseca TCB, Michelli RAD, Mendes DRP, de Paula AE, Viana DV,

Scapultempo-Neto C, Palmero EI. Associação entre triplo-negatividade para câncer de mama,

história familiar positiva e presença de mutações germinativas nos genes BRCA1 e BRCA2.

XXV Congresso Brasileiro de Genética Médica. 11-15 June 2013. Florianópolis, Brazil.

26. Fernandes GC, Mendes DRP, de Paula AE, Michelli RAD, Viana DV, Palmero EI. Padrão

heterogêneo de desenvolvimento tumoral em famílias portadoras da mutação germinativa

p.R337H no gene TP53: implicações para o Aconselhamento Genético e seguimento. XXV

Congresso Brasileiro de Genética Médica. 11-15 June de 2013, Florianópolis, Brazil.

27. Giacomazzi J, Graudenz M, Osorio CA, Koehler-Santos P, Palmero EI, Michelli R,

Fernandes GC, Scapulatempo-Neto C, Achatz MIW, Martel-Planche G, Soares FA, Caleffi M,

Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P. Association between the founder

brazilian TP53 p.R337H mutation and HER2-positive status. In: ASCO Annual 2013 Meeting

- Building Bridges to Conquer Cancer, 2013, Chicago, USA.

28. Guimarães DP, Carvalho E, Cunha T, Oliveira K, Viel A, Fava G. Combinação entre

Mitomicina-C e Prótese Plástica Auto-expansivel no Tratamento Endoscópico das Estenoses

Benignas Refratárias à Dilatação Endoscópica: Relato de Caso. XII Semana Brasileira do

Aparelho Digestivo. 24-27 November 2013, Goiânia, Brazil.

29. Lacerda CF, Carloni AC, Scapulatempo-Neto C, Crema E, de Arruda Henry M, Rodrigues

MA, de Oliveira AT, Guimaraes DP, Reis RM. TP53 Gene Mutations in Squamous Cells

Carcinoma of the Esophagus Associated with Chagasic Megaesophagus. III Simpósio em

Oncologia Translacional do Hospital de Câncer de Barretos. 29-30 August de 2013, Barretos,

Brazil.

30. Lourenço T, Gonçalves CS, Xavier-Magalhães A, Pinto F, Reis RM, Costa BM.

Relevance of HES1 expression in human gliomas: molecular and clinical correlates. XXII

Porto Cancer Meeting. 11-12 April 2013, Porto, Portugal.

31. Macedo T, Evangelista AF, Marino AFL, Oliveira RJS, Vieira RAC, Longatto AF, Silva

VAO, Vidal DO, Marques MMC. Functional assays of mir-183 and mir-494 in breast cancer

cell lines. III Simpósio em Oncologia Translacional do Hospital de Câncer de Barretos. 29-30

August de 2013, Barretos, Brazil.

32. Macedo T, Evangelista AF, Marino AFL, Vieira RAC, Longatto AF, Silva VAO, Vidal

DO, Marques MMC. miR-183 and miR-494 as risk biomarkers for breast cancer development.

International Congress of Markers in Cancer. 7–9 November de 2013. Brussels, Belgian.

33. Marino ALF, Macedo T, Longatto AF, Kerr LM, Vieira RAC, Evangelista AF, Silveira

HCS, Marques MMC. MicroRNA profiling as a risk biomarker in the development of breast



cancer metastasis. III Simpósio em Oncologia Translacional do Hospital de Câncer de

Barretos. 29-30 August de 2013, Barretos, Brazil.

34. Martinho O, Reis RM. Role of AXL knockdown in the prediction of sunitinib therapy

response in glioblastoma. VI Congresso Nacional da Associação Portuguesa de Neuro-

Oncologia. 15-16 November 2013, Almada, Portugal.

35. Miranda-Gonçalves V, Honavar M, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, Costa

P, Reis RM, Baltazar F. MCT1 plasma membrane expression at hypoxic regions could be a

mediator of cellular aggressiveness in glioblastoma. VI Congresso Nacional da Associação

Portuguesa de Neuro-Oncologia. 15-16 November 2013, Almada, Portugal.

36. Morais-Santos F, Pinheiro C, Vieira A, Paredes J, Schmitt F, Baltazar F. Exploitation of

Monocarboxylate Transporter 1 (MCT1) as target in breast cancer therapy. XXII Porto Cancer

Meeting. 2013, Porto, Portugal.

37. Morais-Santos F, Pinheiro C, Vieira A, Paredes J, Schmitt F, Baltazar F.

Monocarboxylate Transporters as therapeutic targets in breast cancer. Advances in Molecular

Oncology: Translating Molecular Biology into Cancer Treatment. 2013, São Paulo, Brazil.

38. Morais-Santos F, Pinheiro C, Vieira A, Paredes J, Schmitt F, Baltazar F. Contribution of

monocarboxylate transporters to the aggressive phenotype of breast cancer. 11th International

Congress on Targeted Anticancer Therapies. 2013, Paris, France.

39. Oliveira-Silva RJ, Martinho O, Carvalho AL, Reis RM. Testing a novel irreversible anti-

EGFR drug for head and neck cancer treatment. XLII Reunião Anual da SBBq. May 2013,

Foz do Iguaçu, Brazil.

40. Oliveira K, Guimarães DP, Cunha T, Almodova E, Viel A, Scapulatempo-Neto C, Barro

G, Fava G. O Papel da Colonoscopia em Pacientes Submetidos ao Transplante de Medula

Óssea Alogênico com Diagnóstico de Doença do Enxerto Contra Hospedeiro Agudo. XII

Semana Brasileira do Aparelho Digestivo. 24-27 Novembers. 2013, Goiânia, Brazil.

41. Osório NS, Rodrigues F, Garcia EA, Costa MJ. Medical Students Cell Drawings as

Snapshots of Cellular Anatomy Understanding. Association for Medical Education in Europe

(AMEE). 24-28 August 2023, Prague, Czech Republic.

42. Pereira MS, Viana-Pereira M, Jones C, Reis RM. SPINT2 hypermethylation – a common

event in high-grade gliomas. Translating Molecular Biology into Cancer Treatment. SPSAS –

São Paulo School of Advanced Sciences, Advances in Molecular Oncology. February 2013,

São Paulo, Brazil.

43. Pereira MS, Viana-Pereira M, Pardal F, Amorim J, Melo-Pires, Pinheiro C, Lopes JM,

Honavar M, Costa P, Pimentel J, Jones C, Reis RM. Unraveling the Biological Role of


SPINT2 in Gliomas. VI Congresso Nacional da Associação Portuguesa de Neuro-Oncologia,

15-16 November 2013, Almada, Portugal.

44. Pojo M, Gonçalves SC, Xavier-Magalhães A, Fernandes R., Gonçalves T, Rodrigues AJ,

Costa S, Pinto L, Reis R M, Rocha M, Costello JF, Sousa N, Costa B. M. A Transcriptomic

Signature Mediated by HOXA9 Sustains Human Glioblastoma Aggressiveness, Resistance to

Chemotherapy and Glioma Initiation. EACR Summer Conference: Cancer Genomics. 25-28

June 2013, Cambridge, England.

45. Pojo M, Gonçalves SC, Xavier-Magalhães A, Fernandes R, Gonçalves T, Rodrigues J,

Costa S, Pinto L, Reis RM, Rocha M, Costello J F, Sousa N, Costa B. M. HOXA9 Promotes

Glioma Initiation and Sustains Human Glioblastoma Aggressiveness and Resistance to

Therapy. XXII Porto Cancer Meeting & III Porto-Bordeaux Joint Meeting. 11-12 April2013,

Porto, Portugal.

46. Ramos MC, Cury FP, Scapulatempo-Neto C, Silveira HC. Análise comparativa para

seleção de Micronúcleos em células esfoliadas da mucosa bucal preparados por citologia de

base liquida. V Encontro Científico do Hospital de Câncer de Barretos, 2013. Barretos, Brazil.

47. Rodrigues AL, Evangelista AF, Macedo T, Oliveira RJS, Mota AL, Reis RM, Marques

MM. Molecular signatures of microRNAs on human breast cancer cell lines exposed to

Cediranib. III Simpósio em Oncologia Translacional do Hospital de Câncer de Barretos. 29-

30 August 2013. Barretos, Brazil.

48. Rosa MN, Silva VAO, Tansini A, Jones C, Lima JP, Pianowski LF, Reis RM. In Vitro

Activity of euphol from Euphorbia tirucalli on a large panel of human cancer cell lines. XLII

Reunião Anual da SBBq. May 2013, Foz do Iguaçu, Brazil.

49. Scapulatempo-Neto C, Carlos C, Viana L, Miziara JE, Pereira R, Reis RM. Frequência de

mutação de EGFR e KRAS em carcinoma não pequenas células do pulmão na população

brasileira e sua correlação com marcadores genéticos de ancestralidade. XXIX Congresso

Brasileiro de Patologia. 13-16 November 2013, Florianópolis, Brazil.

50. Scapulatempo-Neto C, Faria EF, Saber G, Fregnani JH, Záccaro-Silva LC. Achados

histopatológicos de biópsia prostática: Análise da concordância entre a avaliação de um

centro não oncológico e sua revisão em um centro oncológico numa instituição brasileira.

XXIX Congresso Brasileiro de Patologia. 13 -16 November 2013, Florianópolis, Brazil

51. Scapulatempo-Neto C, Stein MD, Fregnani JH, Carvalho TS, Kerr L, Silva SM, Abrahão-

Machado L, Mateus FP, Mafra A, Campacci N, Silva ET, Mauad EC, Longatto-Filho A.

Desempenho do rastreio citológico cérvico-vaginal em pacientes submetidas à radioterapia

pélvica e braquiterapia vaginal, utilizando o sistema computadorizado Focal Point: Resultado


do estudo RODEO. XXIX Congresso Brasileiro de Patologia. 13-16 November 2013,


52. Scapulatempo-Neto C, Watanabe A, Pereira CAA, Vieira RA, Silva ECA, Yamashita T,

Relato de caso: Amiloidose primária da mama formando massa e microcalcificações suspeitas

à mamografia. XXIX Congresso Brasileiro de Patologia. 13-16 November 2013,


53. Silva ECA, Abrahão-Machado L, Carvalho TS, Souza W, Almeida GC, Matsushita M,

Santana IV, Scapulatempo-Neto C. Carcinoma hepatóide primário do ovário: Um raro relato

de caso. XXIX Congresso Brasileiro de Patologia. 13-16 November 2013, Florianópolis,

Brazil.

54. Silva ECA, Abrahão-Machado L, Santana IV,, Scapulatempo-Neto C, Souza W, Silva

SFA. Tumor sólido pseudopapilífero do pâncreas em uma mulher de meia idade: Relato de

um caso com apresentação clínico-patológica incomum. XXIX Congresso Brasileiro de

Patologia. 13-16 November 2013, Florianópolis, Brazil.

55. Silva V, Rosa MN, Tansini A, Lima JP, Jones C, Pianowski LF, Reis RM. Cytotoxic

activity of semi-synthetic ingenol derived from Euphorbia tirucalli on a large panel of human

cancer cell lines. 2013 ASCO Annual Meeting. May 2013, Chicago, USA.

56. Silva VAO, Rosa MN, Tansini A, Lima JP, Jones C, Pianowski LF, Reis RM. Cytotoxic

effect of euphol from Euphorbia tirucalli on a large panel of human cancer cell lines. 2013

ASCO Annual Meeting. May 2013, Chicago, USA.

57. Silva VAO, Rosa MN, Tansini A, Vazquez V, Pianowski LF, Reis RM. Cytotoxic effect

of euphol and semi-synthetic ingenol derived from Euphorbia tirucalli on human melanomas

cell lines. 8th World Congress of Melanoma. July 2013, Hamburg, Germany.

58. Silva VAO, Rosa MN, Tansini A, Costa AM, Oliveira-Silva R, Martinho O, Pianowski L,

Reis RM. The semi-synthetic ingenol c derived from Euphorbia tirucalli induces cell death via

autophagy but not apoptosis in human glioma cancer cells. III Congresso Luso-Brasileiro de

patologia experimental (XIII Simpósio Internacional sobre técnicas experimentais). 23-25

October 2013, Tiradentes, Minas Gerais, Brazil.

59. Silva VAO, Rosa MN, Tansini A, Pianowski LF, Reis RM. In vitro cytotoxic activity of

am11 and semi-synthetic ingenol derived from Euphorbia tirucalli on a large panel of human

cancer cell lines. III Congresso Luso-Brasileiro de patologia experimental (XIII Simpósio

Internacional sobre técnicas experimentais). 23-25 October 2013, Tiradentes, Minas Gerais,

Brazil.


60. Silva VAO, Rosa MN, Tansini A, Costa AM, Oliveira-Silva R, Martinho O, Pianowski L,

F, Reis RM. The semi-synthetic ingenol c derived from Euphorbia tirucalli induces cell death

via autophagy but not apoptosis in human glioma cancer cells. V Encontro Científico do

Hospital de câncer de Barretos . 13-14 Decembre 2013, Barretos, SP, Brazil.

61. Torrieri R, Lima JP, Reis RM. In silico analysis of the raf kinase inhibitory protein (RKIP)

expression impact in breast cancer patients. III Simpósio em Oncologia Translacional do

Hospital de Câncer de Barretos. 29-30 August 2013, Barretos, Brazil.

62. Xavier-Magalhães A, Gonçalves SC, Lourenço T, Pojo M, Rocha M, Lopes MC, Crespo I,

Rebelo O, Tão H, Moreira R, Pinto AA, Reis RM, Costello JF, Sousa N, Costa BM. Long

Non-Coding RNA HOTAIR is Transcriptionally Activated by HOXA9 and Is Associated

with Poor Prognosis in Glioblastoma. XXII Porto Cancer Meeting & III Porto-Bordeaux Joint

Meeting. 11-12 April 2013, Porto, Portugal.

63. Xavier-Magalhães A, Gonçalves SC, Lourenço T, Pojo M, Rocha M, Lopes MC, Crespo I,

Rebelo O, Tão H, Moreira R, Pinto AA, Reis RM, Costello JF, Sousa N, Costa BM. Long


with Poor Prognosis in Glioblastoma. Non-coding RNA, epigenetics and transgenerational

inheritance. 11-12April 2013, Cambridge, England.

64. Xavier-Magalhães A, Gonçalves SC, Lourenço T, Pojo M, M, Rocha Lopes M C, Crespo

I, Rebelo O, Tão H, Moreira R. Pinto A A, Reis RM, Costello JF, Sousa N, Costa BM. Long


with Poor Prognosis in Glioblastoma. SPSAS - Advances in Molecular Oncology: Translating

Molecular Biology into Cancer Treatment. 3-8 February 2013, São Paulo, Brazil.

65. Viana DV, Viana-Pereira M, Almeida G, Clara C, Palmero E, Scapulatempo Neto C,

Jones C, Bertuzzo CS, Reis RM. Biallelic mutations in MMR gene in a retrospective series of

CNS tumors. IV Annual IMPPC Conference/1st ICO-IDIBELL Hereditary Cancer Program

Meeting. Hereditary and Familial Cancer In The Personal Genomics Era.14-15 March 2013,

Barcelona, Spain.

66. Volpe FAP, Doretto AS, Rezende FF, Freitas JA, Garcia EA. Public health units as

learning scenario for medical students. Association for Medical Education in Europe (AMEE).

24 -28 August 2013, Prague, Czech Republic.

67. Zanon MF, Almeida GC, Matsushita MM, Reis RM, Squire JA, Camparotto ML.

Evaluation of 1p/19q codeletion using FISH analysys in pure and mixed oligodendroglial

tumors at the routine pathology of the Barretos Cancer Hospital-SP, Brazil. III Simpósio em


Oncologia Translacional do Hospital de Câncer de Barretos. 29-30 August 2013, Barretos,

Brazil.

6) Science Communication to general public

1. Reis RM, Carvalho AL: Revista Hospital do Futuro, HdF Nº15, Portugal – O Hospital de

Câncer de Barretos.

2. Lacerda CF, de Oliveira AT, Guimaraes DP, Reis RM. Câncer de Esôfago, da Clínica a

Biologia Molecular. Revista Onco& – oncologia para todas as especialidades. Nov/Dec, 2013

3. Palmero EI. Hereditariedade e Câncer de Mama” Revista Onco & – oncologia para todas as

especialidades. Sept/Oct, 2013

4. Silveira HCS, Lopes LF. Alunos acompanham luta contra o câncer em Hospital de Barretos.

Portal G1, Barretos, 15 July, 2013.

5. Silveira HCS . Concurso de Redação do HC. O Diário, Barretos, 14 July, 2013.

6. Silveira HCS . I Concurso de Redação. Jornal de Barretos, Barretos, 06 July. 2013.

7) Supervision of PhD, Master and Initiation to Trainee Fellows

7.1) PhD

1. Adriana Lorenzi. Valor do teste careHPV de captura híbrida em Unidade Móvel no rastreio

do câncer cervical em áreas rurais e remotas. HCB (Supervision - Longatto Filho, A.). 2011 –

present.

2. Aline Nazareth de Paiva Paixão Becker. Avaliação da via MAPK na oncogênese dos

astrocitomas pilocíticos. HCB (Supervision – Reis RM, Co-supervision- Scapulatempo-Neto

C). 2012 – present.

3. Filipe Pinto. Learning from the embryo: Understanding early embryonic T gene -

Brachyury - impact in human tumorigenesis. ICVS, Universidade do Minho (Supervision –

Reis RM). 2011-present.

4. Gustavo Berardinelli. Elucidação do impacto molecular e clínico da instabilidade de

microssatélite em pacientes com câncer colorretal esporádico do Hospital de Câncer de

Barretos. HCB (Supervision – Reis RM). 2013 – present.

5. Herlander Jose Resende Marques. Prevalência de vírus Herpes nos Linfomas Foliculares

Influência dos polimorfismos dos sistemas apresentadores de antigénio na infecção crónica.

ICVS, Universidade do Minho. (Supervision - Longatto Filho A). 2008 - 2013.


6. Julieta Alexandra Pereira Afonso. The Biology of Lymphatic Spread of Urothelial Bladder

Cancer. ICVS, Universidade do Minho. (Supervision - Longatto Filho A). 2008 - 2013.

7. Junea Caris de Oliveira. Correlação genotipo-fenotipo em pacientes portadores de Polipose

Adenomatosa Familial. HCB (Supervision – Rossi BM, Co-supervision- Palmero EI). 2012 –

present.

8. Leonado Gabeira Secco. Fatores Prognósticos em Carcinoma Bem Diferenciado da

Tireóide. FMUSP (Supervision – Carvalho AL). 2005-present.

9. Maria Teresa Roncaglia. O valor da captura híbrida para HPV no seguimento de pacientes

com neoplasia intra-epitelial de alto grau submetidas à conização do colo uterino por cirurgia

de alta freqüência. FMUSP (Supervision –Longatto Filho A). 2010- present.

10. Roberta Targa Stramandinoli. Avaliação da interface osso/implante em mandíbula de

miniporcos irradiados e o uso de biomateriais na osseointegração. FMUSP (Supervision –

Carvalho AL). 2010-present.

11. Sandra Fátima Fernandes Martins. Expression of Colorectal Cancer Metabolic and

Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on

Prognosis. ICVS, Universidade do Minho. (Orientação Longatto Filho L). 2008 - 2013.

12. Thiago Buosi Silva. Desenvolvimento e validação de nomogramas para estimar os riscos

de câncer de próstata e de câncer de próstata de baixo e alto grau de malignidade. FMUSP

(Supervision – Carvalho AL). 2010-2013

13. Renato José da Silva Oliveira. Identificação de novos biomarcadores preditivos da

resposta à terapia anti-EGFR em tumores sólidos. HCB (Supervision – Reis RM, Co-

supervision- Carvalho AL). 2011 – present.

14. Flávio Mavignier Cárcano. Estudo da instabilidade de microssatélite, ADAMTSI e OCT-

3/4 nos tumores de células germinativas do testículo e suas associações prognósticas

preditivas nos pacientes submetidos à quimioterapia. Hospital de Câncer de Barretos

(Supervision: Lopes LF). 2012-present.

7.2) Master

1. Adriana Cruvinel. Caracterização Citogenética e Molecular de Linhagens Primárias de

Gliomas. Hospital de Câncer de Barretos (Supervision - Reis RM). 2011-2013.

2. Adriano Jander Ferreira. Catalogação dos pacientes com diagnostico de Sarcoma de Ewing

tratados no Hospital de Câncer de Barretos. Hospital de Câncer de Barretos (Supervision -

Lopes LF). 2011 - 2013


3. Ana Laura Bordinhão Rodrigues. Avaliação da expressão de microRNAs em linhagens

celulares de carcinoma mamário humano expostas a ação do fármaco Cediranib. Hospital de

Câncer de Barretos (Supervision- Marques, MMC). 2011-2013.

4. Augusto Ludvik Filip Marino. Análise do perfil de expressão diferencial de microRNAs

em carcinomas mamários por microarrays. Hospital de Câncer de Barretos (Supervision -

Marques, MMC). 2011-2013.

5. Camila Maria da Silva Martinelli. Avaliação do perfil de metilação de genes alvo

candidatos em tumores de células germinativas do testículo. Hospital de Câncer de Barretos

(Supervision- Lopes LF, Co-supervision- Vidal DO). 2013 – present.

6. Croider Franco Lacerda. Estudo do gene supressor tumoral, TP53, no carcinoma de células

escamosas do esôfago associado ao megaesôfago chagásico. Hospital de Câncer de Barretos

(Supervision - Reis RM, Co-supervision- Guimaraes DP). 2011-2013.

7. Flávia Coltri Eguchi. Avaliação da superexpressão das proteínas TMPRSS2 e ERG e a

fusão gênica TMPRSS2:ERG em portadores de câncer prostático. Hospital de Câncer de

Barretos (Supervision - Campos, SGP). 2011-2013.

8. Gabriela Carvalho Fernandes. Identificação de mulheres em risco para câncer de mama

hereditário por mutação nos genes BRCA1 e BRCA2: contribuição dos dados patológicos,

história familiar e modificadores genéticos do risco de câncer. Hospital de Câncer de Barretos

(Supervision - Palmero EI). 2013-2015.

9. Juliana Levy Daher. Aspectos funcionais e emocionais da deglutição e fonação no paciente

com câncer de cabeça e pescoço pré e pós tratamento oncológico Hospital de Câncer de

Barretos. (Supervision - Carvalho AL). 2011-2013.

10. Júlio Cesar Possati Resende. Detecção de lesão intraepitelial cervical de alto grau em

mulheres com citologia de ASC-US E LIEBG: Comparação entre a expressão

imunocitoquímica dos biomarcadores P16/Ki-67 e teste molecular de DNA-HPV de alto risco.

(Supervision – Scapulatempo-Neto, C). 2012-2014.

11. Letícia Rodrigues Cardoso. Síndrome de Dor Miofascial em pacientes portadores de

câncer de cabeça e pescoço. Hospital de Câncer de Barretos (Supervision - Carvalho AL).

2011-present.

12. Leticia dos Santos Yamane. Estudo mutacional dos oncogeneses KRAS e BRAF nas

lesões do cólon e reto. Hospital de Câncer de Barretos (Supervision – Guimaraes DG, Co-

supervision- Reis, RM). 2011 – 2013.

13. Luiz Cesar Záccaro da Silva. Análise crítica da discrepância entre achados

histopatológicos da biópsia prostática realizada em centros não oncológicos e sua revisão em


um centro oncológico. Hospital de Câncer de Barretos (Supervision - Scapualtempo-Neto C).

2011-2013.

14. Maira DeGiovani Stein. Desempenho diagnóstico da citologia manual versus a citologia

assistida por computador usando BD FocalPoint GS Imaging system em material preparado

em sistema BD SurePath de base líquida. Hospital de Câncer de Barretos (Supervision -

Adhemar Longatto Filho). 2011-2013.

15. Maicon Fernando Zanon da Silva. Avaliação da via de sinalização FGFR1/PI3K/AKT em

carcinomas adenóides císticos. Hospital de Câncer de Barretos (Supervision – Scapulatempo-

Neto C). 2012-2014.

16. Marcelo Simonsen. Comparação da correlação cito-histológica utilizando os diferentes

dispositivos Cytobrush™ e Cervex-Brush Combi™ na coleta de amostras uterinas para

confecção de citologias de base líquida. Hospital de Câncer de Barretos (Supervision

Scapulatempo- Neto C). 2013-2015.

17. Natalia Campacci. Rastreamento populacional de famílias com predisposição hereditária

de câncer de mama e/ou câncer colorretal. Hospital de Câncer de Barretos (Supervision -

Palmero EI). 2011-2013.

18. Nathália Cristina Campanella. Estudo da instabilidade de microssatélite e potenciais

genes alvos em GISTs. Hospital de Câncer de Barretos (Supervision - Reis RM). 2012-2013.

19. Taciane Macedo. Estudo funcional de microRNAs associados ao processo de metástase

em linhagens celulares de carcinoma mamário humano. Hospital de Câncer de Barretos

(Supervision - Marques, MMC) 2012- present.

20. Vanessa Regina Maciel Uzan. Perfil de expressão gênica dos RNAs não codificadores

HOTAIR, MALAT1, HULC e BCYRN1 (BC200) em Osteossarcoma. Hospital de Câncer de

Barretos (Supervision- Lopes LF, Co-supervision- Vidal DO). 2013 – present.

21. Marcelo Simonsen. Comparação do desempenho dos dispositivos de coleta de material

cervical Cervex brush e escova endocervical + espátula de Ayre na detecção de lesões

intraepiteliais (Supervision- Scapulatempo-Neto C). 2013- present.

22. Júlio César Possati Ribeiro. Comparação entre o teste molecular COBAS e a co-expressão

de ki-67/p16 na detecção de lesões intra epiteliais de alto grau em pacientes com diagnóstico

de ASC-US e LSIL na citologia cérvico vaginal (Supervision- Scapulatempo-Neto C). 2012-

present.

23. Thiago Rabelo da Cunha. Estudo comparativo entre diferentes parâmetros de coagulação

com plasma de argônio no tratamento da retite actínica. (Supervision- Guimarães DP). 2012-

present.


7.3) Trainee Fellows

1. André de Lima Mota. Avaliação da expressão de VEGF e do seu receptor VEGFR-1/Flt-1

e VEGFR-2/Flk-1 em linhagens celulares de carcinoma mamário humano expostas a ação do

fármaco Cediranib. Hospital de Câncer de Barretos (Supervision - Marques MMC).

2. Fernanda de Paula Cury. Análise do potencial risco de câncer na exposição dos

trabalhadores da construção civil a agentes carcinogênicos. HCB (Supervision – Silveira HC).

3. Graziela Sartori. Caracterização molecular em melanomas acrolentiginosos e das mucosas.

Hospital de Câncer de Barretos (Supervision - Vazquez VL).

4. Juliana Oliveira de Lima. Rastreamento populacional de famílias com predisposição

hereditária de câncer de mama e/ou câncer colorretal. Hospital de Câncer de Barretos, HCB.

(Supervision - Palmero EI).

5. Lamis Ramadan. Desenvolvimento de estrategias educativas para famílias com

predisposição hereditária ao câncer de mama e/ou câncer colorretal. Hospital de Câncer de

Barretos, HCB. (Supervision - Palmero EI).

6. Talitha Cezareti Blau Fonseca. Identificação de mulheres em risco para câncer de mama

hereditário por mutação nos genes BRCA1 e BRCA2: contribuição dos dados patológicos,

história familiar e modificadores genéticos do risco de câncer. Hospital de Câncer de Barretos

(Supervision - Palmero EI)

7. Verônica Rissati. Validação de novas estratégias para identificação de indivíduos em risco

para câncer hereditário.. Hospital de Câncer de Barretos (Supervision - Palmero EI).

8. Manuela Catarina Aguena souza Ramos. Análise comparativa para seleção de

Micronúcleos em células esfoliadas da mucosa bucal preparados por citologia de base liquida.

Hospital de Câncer de Barretos, HCB. (Supervision - Silveira HC).

8) Prizes

1. IV Octavio Frias de Oliveira Prize in the categorie of Research on Oncology with

Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from

head and neck squamous cell carcinoma patients. Rettori MM, de Carvalho AC, Bomfim

Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL, Vettore AL. 05 August 2013.

2. Best Scientific Research work at the III Simpósio em Oncologia Translacional do Hospital

de Câncer de Barretos, with The importance of molecular characterization of head and neck


cancer cell lines for the prediction of anti-EGFR therapies resistance.” Oliveira-Silva, RJ,

Martinho O, Berardinelli GN, Viana L, Carvalho AL, Reis RM. 29-30 August 2013.

3. Honour Mention at the III Congresso Luso-Brasileiro de Patologia Experimental.

Tiradentes, Minas Gerais, with “The semi-synthetic Ingenol C derived from Euphorbia

tirucalli induces cell death via autophagy but not apopotosis in human glioma cancer cells.

Silva, VAO, Rosa MN,Tansini A,Costa AM, Oliveira-Silva R, Martinho O, Pianowski LF.

Reis RM. 23- 25 October 2013.

4. Best Poster at XXII Porto Cancer Meeting & III Porto-Bordeaux Joint Meeting, with

"HOXA9 Promotes Glioma Initiation and Sustains Human Glioblastoma Aggressiveness and

Resistance to Therapy."Pojo M, Gonçalves SC, Xavier-Magalhães A, Fernandes R, Gonçalves

T, Rodrigues AJ, Costa S;Pinto L, Reis RM, Rocha M, Costello, JF, Sousa N, Costa BM.

Portugal, 2013.

5. Best Poster at V Encontro Científico do Hospital de Câncer de Barretos, with The semi-

synthetic ingenol c derived from Euphorbia tirucalli induces cell death via autophagy but not

apoptosis in human glioma cancer cells. Silva VAO, Rosa MN, Tansini A, Costa AM,

Oliveira-Silva R, Martinho O, Pianowski LF, Reis RM. December, Barretos, Brazil, 2013.

6. Best Scientific Work (Gizele Rozone de Luca Award) at XXV Congresso Brasileiro de

Genética Médica, with “Utilização das unidades móveis e fixa de prevenção para

rastreamento populacional de famílias com predisposição hereditária de câncer de mama”.

Campacci N, Lima JO, Rossati V, Toledo EMP, Ramadan L, Palmero EI. Florianópolis, Brazil,

2013.

7. Honour Mention at the I Encontro de Jovens Talentos do Hospital de Câncer de Barretos,

with Assessment of genotoxic damages in civil construction workers using micronucleus

assay. Cury FP, Ramos MC, Scapulatempo-Neto C, Silveira HC. Barretos, Brazil, 2013.

9) Participation in Internacional Networks

1. Carvalho AL, Silveira HC, Reis RM. International Cancer Genome Consortium. 2012-

present.

2. Carvalho AL, Marques MMC, Reis RM, Scapulatempo-Neto C - US-Latin American

Cancer Research Network (USLACRN). 2010-present.

3. Carvalho AL, Mauad EC- WIN - World Innovative Networking, 2010-present.

4. Carvalho AL- INTERCHANGE – Head and Neck Study Group (IARC), 2010-present.

5. Carvalho AL, Silveira HC. The Cancer Genome Atlas (TCGA). 2013 – present.


6. Mauad EC, Carvalho AL, Reis RM, Scapulatempo-Neto C – GAP – Global Academic

Program – Sister Institution Network (MDANderson). 2011-present.

7. Reis RM - IMMEnSE (International Multiple Myeloma rESEarch) consortium – 2010-

present.

8. Reis RM - Société Internationale d'Oncologie Pédiatrique (SIOP) - Brain Tumour

Committee- High Grade Glioma Working Group. 2010-present.

10) Participation in National Networks

1. Carvalho AL, Scapulatempo-Neto C – GENCAPO – Projeto de Genoma Cabeça e Pescoço

Brasileiro, 2010-present.

2. Palmero EI, Reis RM. Rede Brasileira de Câncer Familiar

3. Silveira HC – INAIRA - Instituto Nacional de Análise Integrada do Risco Ambiental

(INCT)

11) Organization of Conferences and Meetings

1. Carvalho AL, Fregnani JH, Longatto Filho A, Scapulatempo Neto C, Vidal DO, Palmero E,

Silveira H, Marques MM, Viana L, Serrano SV, Reis RM. III Simpósio Internacional em

Oncologia Translacional do Hospital de Câncer de Barretos, August, 2013.

2. Lopes LF. II Encontro Internacional de Oncologia Pediátrica de Barretos, March, 2013.

12) Lectures / Seminars at Conferences and Meetings

1. Guimarães DP. XII Semana Brasileira do Aparelho Digestivo. Caracterização Endoscópica

de Adenomas Serrilhados Sésseis. 2013, Goiânia, Brazil.

2. Mariano VS. V Jornada de Integração das ligas de Biomedicina. O papilomavírus humano

como agente causador de câncer. 2013, Ribeirão Preto, São Paulo, Brazil.

3. Longatto AF. Patologia molecular en el diagnostico oncológico, Universidad de La

Republica Uruguaya, Screening en Cáncer Cervical: Nuevo Era Nuevos Paradigmas. 16-17

May 2013, Montevideo, Uruguai.

4. Longatto AF. 18th International Congress of Cytology. Cervical câncer prevention in

Barretos region, Brazil. 26-30 May 2013, Paris, France.


5. Longatto AF. The EUROGIN 2013. Screening: molecular-based strategies careHPV. 3-6

November 2013, Florence, Italy.

6. Longatto AF. VIII Congreso Latinoamericano de Patologia Del Tracto Genital Inferior y

Colposcopia. Prevención de cáncer cervical en Latinoamérica. 13-15 November 2013, Buenos

Aires, Argentina.


Colposcopia. Diagnóstico citopatológico y molecular en El TGI - Diagnótico citológico y

anatomopatológico de la ZT. 13-15 November 2013, Buenos Aires, Argentina.


Colposcopia. HPV. Biologia molecular y respuesta inmune’. Marcadores pronósticos de La

lesión inducida por HPV. 13-15 November 2013, Buenos Aires, Argentina.

9. Lopes LF. XI Congresso de Saúde e Qualidade de Vida do Cone Leste Paulista. Banco de

tumores pediátricos no auxílio a pesquisa tranlacional e a aplicação a prática clínica da

oncologia pediátrica. 2013. UNIVAP-São José dos Campos, São Paulo, Brazil.

10. Lopes LF. II Encontro do Comitê de Sindromes Mielodisplásticas da ABHH. Grupo

Brasileiro de SMD pediátrica: sucessos e dificuldades. 2013, São Paulo, São Paulo, Brazil.

11. Lopes LF. I Encontro Nacional dos Profissionais de Pesquisa Clínica em Oncopediatria no

XIV Encontro Nacional de Grupos Cooperativos. Tumores de células germinativas. 2013. São

Paulo, São Paulo, Brazil.

12. Lopes LF. II Encontro Internacional de Oncologia Pediátrica de Barretos. Tumor de

células germinativas: dados do grupo brasileiro. 2013, Barretos, São Paulo, Brazil.

13. Lopes LF. II Encontro Internacional de Oncologia Pediátrica de Barretos. SMD da

infância: histórico e dados epidemiológicos. 2013, Barretos, São Paulo, Brazil.

14. Lopes LF. 45° Congresso da Sociedade Internacional de Oncologia Pediátrica. 2013,

Hong Kong, China.

15. Lopes LF. III Jornada Latino Americana- Israelense de Hemantologia Pediátrica e 7ª

Renião Científica Anual do Grupo Galop. Tumores de Células Germinativas- Resultados de

TCG 2008. 2013. Montevideo, Uruguai.

16. Lopes LF. Congresso Brasileiro de Hematologia e Hemoterapia da ABHH. Avanços na

Patonense e tratamento da Leucemia Mielomonocitica Juvenil. Brasília, Brazil.

17. Lopes LF. GAP 2013 Meeting. The Brazilian cooperative Group on Pediatric

Myelodyplastic syndrome from 1997 to 2012: is it relevant to improve educational approach

and correct diagnosis. 2013 Houston, USA.


18. Pinheiro C. III International Symposium on Translational Oncology of the Barretos

Cancer Hospital. Therapeutic targeting of cancer metabolism: exploitation of

monocarboxylate transporters.29-30 August 2013, Barretos, Brazil.

19. Palmero EI. III International Symposium on Translational Oncology of the Barretos

Cancer Hospital. The interplay between research and clinics in hereditary cancer, 29-30

August 2013, Barretos, Brazil.

20. Palmero EI. XXV Congresso Brasileiro de Genética Médica. Importância do diagnóstico

molecular para a identificação dos indivíduos em risco. 2013, Florianopolis, Brazil.

21. Palmero EI. Ion World 2013 - Next Generation Sequencing: From Bench top to the

Clinic. Applications of Next-Generation Sequencing in Oncology. 2013, São Paulo, Brazil.

22. Reis RM. I Simpósio de Pesquisa Clínica do Hospital de Câncer de Barretos. Pesquisa

Translacional: o que esperar do future? 29 November 2013, Barretos, Brazil.

23. Reis RM. I Jornada de Cirurgia Hepatobiliopancreática do HUGG. Biologia Molecular no

tratamento Onco-Cirúrgico. 28-30 October 2013, Rio de Janeiro, Brazil.

24. Reis RM. Meeting de Gliomas, Universidade Federal da Bahia (UFBA), Instituto de

Ciências da Saúde (ICS). Biologia Molecular de Gliomas: Impacto Clínico. 23 October 2013,

Salvador, Brazil.

25. Reis RM. III Simpósio Internacional de Oncologia Translacional do Hospital de Câncer

de Barretos. The role of RTKs signaling in gliomas. 29-30 August 2013. Barretos, Brazil.

26. Reis RM. World Innovative Networking (WIN) 2013. Challenges and opportunities in the

implementation of personalized medicine in Brazil. July 2013, Paris, France.

27. Reis RM. XVI Pathology Meeting of A. C. Camargo Cancer Center and VI International

Meeting on Investigative Pathology. The role of RTKs and the downstream MAPK pathway

in glioma biology and therapy. 7-9 August 2013, São Paulo, Brazil.

28. Reis RM. 1er Curso en Patologia Molecular Diagnostica Terapêutica e Investigativa.

Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos. 16-17 May

2013, Montevideo, Uruguai.

29. Reis RM. 1er Curso en Patologia Molecular Diagnostica Terapeutica e Investigativa.

Bases Moleculares en el Diagnostico y Terapeutica en Cancer. 16-17 May 2013, Montevideo,

Uruguai.

30. Scapulatempo CN. III International Symposium on translational oncology of The Barretos

Cancer Hospital. Recent genomic discoveries with potential impact in personalized medicine.

29-30 August. Barretos, Brazil.


31. Scapulatempo CN. Practicas em Patología Molecular. Primeiro Curso em Patologia

Molecular Diagnóstica Terapêutica e Investigativa. 16-17 May 2013, Hospital de Clínicas de

Montevideo, Uruguai.

32. Scapulatempo CN. Discussão de Casos-Clinicos. Patología Molecular. Primeiro Curso em

Patologia Molecular Diagnóstica Terapêutica e Investigativa. 16-17 May 2013, Hospital de

Clínicas de Montevideo, Uruguai.

33. Scapulatempo CN. Seminário de Lâminas- Citologia. XXIX Congresso Brasileiro de

Patologia. 13-16 November 2013, Florianopolis, Brazil.

34. Scapulatempo CN. Como eu diagnóstico carcinoma escamocelular versus

adenocarcinoma em pequenas amostras de biópsia pulmonar. XXIX Congresso Brasileiro de

Patologia. 13-16 November 2013, Florianopolis, Brazil.

35. Scaputatempo CN. Seminário de Lâminas - Patologia cirúrgica: Armadilhas em patologia

cirúrgica. XXIX Congresso Brasileiro de Patologia. 13-16 November 2013, Florianopolis,

Brazil.

36. Silveira H. III International Symposium on Translacional Oncology. Risk assessment on

occupationally exposed populations. 29-30 August 2013, Barretos, Brazil.

37. Marques MCM. III International Symposium on Translational Oncology of the Barretos

Cancer Hospital. MicroRNAs as biomarkers in breast cancer. 29-30 August 2013, Barretos,

Brazil.

38. Marques MM. Controle pos-transcricional da expressão genica por microRNAs.

Universidade Federal de São Carlos. 21 November 2013, São Carlos, Brasil.

39. Vazquez VL. 10ª Conferencia Brasileira de Melanoma- linfadenectomia video assistida.

2-3 August 2013. Belo Horizonte, Brazil.

40. Vazquez VL. XI Congresso da Sociedade Brasileira de Cirurgia Oncológica-

linfadenectomia video assistida. 17-19 October 2013. São Paulo, Brazil.

41. Vidal DO. II Encontro Internacional de Oncologia Pediátrica de Barretos. Síndrome

Mielodisplásica da Infância: Estudos de Biologia Molecular: revisão da literatura e dados

brasileiros. 22-25 March 2013. Barretos, Brazil.

42. Vidal DO. II Curso Avançado em Citogenômica do Câncer: Abordagem teórico-prática

em Citogenétia e Biologia Molecular aplicada a onco-hematologia. Epigenética em onco-

hematologia. 20–23 November 2013, Fortaleza, Brazil.

43. Vidal DO. II Curso Avançado em Citogenômica do Câncer: Abordagem teórico-prática

em Citogenétia e Biologia Molecular aplicada a onco-hematologia. Epigenética e Câncer:

conceitos teóricos. 20–23 November2013, Fortaleza, Brazil.


13) Funding

13.1) Governmental Agencies

1. Análise de metilação em câncer de cabeça e pescoço

Funding Agency: FAPESP (R$ 350.000)

CPOM -Hospital de Câncer de Barretos (R$ 70.000)

Duration: 2010-2013

PI: Eloiza Tajara, Membros, André Lopes Carvalho, Matias Melendez

2. Avaliação do papel de microRNAs diferencialmente expressos no controle de invasão e

metástase do câncer de mama

Funding Agency: FAPESP (R$ 300.000,00)

CPOM -Hospital de Câncer de Barretos (R$ 300.000,00)

Duration: 2011-2013

PI: Márcia MC Marques

3. Chamada CNPq Nº 014/2011- Caracterização da instabilidade genômica em glioblastomas:

identificação e elucidação de novas vias moleculares em tumores e culturas primárias”

Funding Agency: CNPq Universal (R$113.356,00)

CPOM -Hospital de Câncer de Barretos (R$113.356,00)

Duration: 2012-2013

PI: Rui M Reis

4. Instituto Nacional de Ciência E Tecnologia para o estudo de papilomaviroses humanas

Agências de Fomento: CNPq - Auxílio financeiro / FAPESP - Auxílio financeiro

(R$7.000.000)

CPOM -Hospital de Câncer de Barretos (R$507.360,00)

Duration: 2009 – 2013

PI: Luisa Lina Villa, Membro - Adhemar Longatto Filho

5. Implantação do Centro de Prevenção - Edital FINEP - CT-INFRA - 01/2012

Funding Agency: FINEP (R$ 1.551.241,00)

CPOM -Hospital de Câncer de Barretos

Duration: 2012-2013

PI: André L. Carvalho; Adhemar Longatto-Filho


6. Decifrando o papel dos pyknons não-codificantes no câncer colorretal

Funding Agency: SINF-MDAnderson Cancer Center (USAdollars – 100.000,00)


Duration: 2012-2014

PI: George Calin, Membro; Rui M Reis

7. Avaliação do papel biológico e clínico de alterações nas vias moleculares RAS-MAPK e

PI3K-AKT , em melanomas cutâneos e de mucosa em população brasileira e comparação com

a população estadunidense

Funding Agency: FAPESP/fluxo contínuo – auxílio financeiro (R$ 209.186,00).

CPOM-Hospital de Câncer de Barretos

Duration: 2012-2014

PI: Vinicius de Lima Vazquez

8. Transportadores de monocarboxilatos como potenciais alvos terapêuticos em câncer:

estudos de expressão e de inibição em tumores de células germinativas

Funding Agency: CNPq- Universal 14/2013 (R$24.000,00)


Duration: 2014-2017

PI: Céline Pinheiro

9. Nova abordagem para o tratamento de células de glioblastoma com deleção de MTAP



Duration: 2014-2017

PI: Lucas Bidinotto

10. Estudo do papel biológico e terapêutico da Raf kinase inhibitor protein (RKIP) em GISTs

e sua correlação com o fenótipo de instabilidade de microssatélites (MSI)



Duration: 2014-2017

PI: Rui Manuel Reis

11. Care HPVTM – Captura Híbrida em unidade móvel para melhoria do programa de rastreio

do câncer cervical em áreas restritas e remotas brasileiras

Funding Agency: PPSUS (R$365.374,40)


Duration: 2013-2015


PI: Adhemar Longatto-Filho

12. BIOPLAT – Plataforma Brasileira para Estudos de Bioprospecção de compostos naturias

com potencial anticâncer em fase pré-clínica

Agência de fomento: FINEP (MCTI/FINEP/MS/SCTIE/DECIT-1302/13) (R$1.384.000,00)


Duration: 2014-2016

PI: Rui Manuel Reis

13. Perfil mutacional de linhagens primárias de glioblastomas

Funding Agency: FAPESP/fluxo contínuo – auxílio financeiro (R$ 350.110,00).


Duration: 2013-2015

PI: Rui Manuel Reis

14. Estudo funcional da modulação dos miRNAs, miR-451 e miR-720, em linhagens celulares

de tumores humanos

Funding Agency: FAPESP/ Projeto de Pesquisa – Regular (R$ 200.000,00)

CPOM – Hospital de Câncer de Barretos

Duration: 2013-2015

PI: Daniel Onofre Vidal

15. Estudo do efeito antineoplásico de extratos e derivados de Euphorbia tirucalli em tumores

cerebrais e células tronco tumorais cerebrais

Funding Agency: MCTI/CNPq (73/2013) (R$ 490.748,00)


Duration: 2013-2015

PI: Rui Manuel Reis

16. Avaliação do câncer ocupacional e do potencial risco em trabalhadores rurais expostos a

agentes carcinogênicos ambientais e ocupacionais na região de Barretos

Funding Agency: Ministério da Saúde – Chamamento Publico n°20 – Estudos e Pesquisas

Aplicadas em Vigilância em Saúde

Duration: 2013-2015 (R$ 140.000,00)

PI: Henrique Cesar Santejo Silveira

17. The Cancer Genome Atlas (TCGA)

Funding Agency: NIH

Duration: 2013-2014 (R$ 800.000,00)

PI: André Lopes Carvalho


13.2) Pharmaceutical / Biotechnology Industry

1. Estudo pré-clinico dos potenciais compostos anti-neoplásicos AM10 e AM11.

Industry: Fitomedicamentos Amazônica (R$1.455.963,00)

CPOM -Hospital de Câncer de Barretos (R$1.455.963,00)

Duration: 2012-2015

PI: Rui M Reis

2. Tumores de Origem Primária Desconhecida ou Incerta: Identificação através de um

Diagnóstico Molecular Inovador.

Industry: Laboratório Fleury (R$500.000,00)

Duration: 2012-2014

PI: André Carvalho Lopes

3. Métodos moleculares para rastreamente de lesões de colo uterino induzidas por

Papilomavírus humano.

Industry: Laboratório Fleury (R$500.000,00)

Duration: 2012-2014

PI: Adhemar Longatto Filho

13.3) Individual Grants

13.3.1) Technical Support / Research Initiation

1. Beneficiary: Aline Oliveira da Rocha (TT3)

Agency: FAPESP (R$ 21.650,00)

Duration: 2013-2015

Responsible: Daniel Onofre Vidal

2. Beneficiary: Anna Luiza Almeida (TT3)


Duration: 2012-2014

Responsible: Vinicius Vazquez

3. Beneficiary: Weder Menezes (TT3)


Duration: 2013-2015

Responsible: Rui Manuel Reis

4. Beneficiary: Fernanda Cury


Agency: CNPq (R$ 4.800,00)

Responsible: Henrique Cesar Santejo Silveira

13.3.2) Master

1. Beneficiary: Augusto Ludvik Filip Marino


Duration: 2012-2013

Responsible: Márcia MC Marques Silveira

2. Beneficiary: Nathália Cristina Campanella


Duration: 2012-2013

Responsible: Rui M Reis

3. Beneficiary: Flávia Coltri Eguchi


Duration: 2012-2013

Responsible: Silvana Campos

4. Beneficiary: Taciane Macedo


Duration: 2013-2014


13.3.3) Post-Doc Fellowship

1. Beneficiary: Adriane Feijó Evangelista


Local: CPOM -Hospital de Câncer de Barretos

Duration: 2012-2014


2. Beneficiary: Matias Melendez

Agency: CNPq (R$ 103.000,00)

Duration: 2012-2014

Responsible: André Lopes Carvalho

13.3.4) Exchange Grants

1. Beneficiary: André van Helvoort Lengert


Agency: St. Jude Children’s Research Hospital (U$ 36.000,00)

Duration: July 2012 - June 2013

Country: U.S.A.

Responsible: Daniel Onofre Vidal and Luiz Fernando Lopes.

13.3.5) Excelentce in Research Grants

1. Bolsista de Produtividade em Pesquisa 1D

Funding Agency: CNPq


Duration: 2010-2013

PI: André Lopes Carvalho




Duration: 2011-2014

PI: Adhemar Longatto Filho




Duration: 2011-2014

PI: Rui M Reis

13.3.6) Visiting Professor Grant

1. Funding Agency: CNPq

CPOM - Hospital de Câncer de Barretos

Visiting Porfessor: Kari Juhani Syrianny

Duration: 2012-2014

Responsible: Adhemar Longatto-Filho

14) Patents

Title: Usos de pelo menos um miRNA, kit métodos de diagnóstico de câncer de mama e

métodos para avaliação de risco de metástase.


Identification number: PCT/BR2013/000357

Responsible: Márcia MC Silveira

15) Jury Participartion

15.1) PhD

1. Marques MMC. Danilo Jordão Xavier, Influencia da hiperglicemia sobre perfis de

expressão transcricional de mRNAs e microRNAs em linfócitos de pacientes com Diabetes

Mellitus tipo 2. Departamento de Genética Faculdade de Medicina de Ribeirão Preto, 2013.

2. Marques MMC: Danielle Calheiros Maia. Avaliação do perfil de expressão de microRNAs

como marcadores prognosticos em tumores iniciais de laringe tratados com radioterapia

exclusiva. Universidade Federal de São Paulo, 2013.

3. Lopes LF. Indhira Dias Oliveira. Estudo de expressão genica nos mecanismos de

manutenção de telomeros e de remodelação óssea em osteossarcoma.CUniversidade Federal

de São Paulo, 2013.

4. Reis RM. Rute Maria Ferreira Lima. Caracetrização Fenotípica de ESP12, uma nova

linhagem de células tumorais de glioblastomas humano, e desenvolvimento de um modelos in

vitro para avaliar a resistência de gliomas e quimioterápicos. Patologia Humana e Patologia

Experimental, Universidade Federal de Bahia, FioCruz, Salvador, 2013.

5. Reis RM. Israel Gomy. Análise da Suscetibilidade ao Câncer Colorretal em Indivíduos

Brasileiros por Genotipagem de Polimorfismos de Nucleotídeo Único Conhecidos. Fundação

Antônio Prudente, 2013.

6. Reis RM. Ana Ines Rebelo Crespo. Genetic imbalances and numerical chromosomal

alterations in glioblastomas as assessed by SNP-arrays and their impacto n gene expression.

Universidade de Coimbra, January, 2013.

7. Vidal DO. Lídia Maria Rebolho Batista Arantes. Metilação do DNA e Biomarcadores em

Câncer de Cabeça e Pescoço. Doutorado em Ciências da Saúde - Faculdade de Medicina de

São José do Rio Preto. 2013.

15.2) Master

1. Carvalho AL. Carlos Eduardo Goulart Silveira. HPV-16 Como fator preditivo de

recorrência para lesões intraepiteliais do colo do uterino tratadas cirurgicamente. Hospital de

Câncer de Barretos, 2013.

2. Evangelista AE. Fernanda Bueno Barbosa. CNVs em Lúpus Eritematoso Sistêmico.

Faculdade de Medicina de Ribeirão Preto/USP. 2013.


3. Fregnani JH. Maíra Degiovani Stein. Desempenho diagnóstico da citologia cervical

preparada em base líquida, lida manualmente versus a lida de forma automatizada e assistida

por computador. Hospital de Câncer de Barretos, 2013.

4. Fregnani JH. Letícia dos Santos Yamane. Caracterização mutacional dos oncogenes KRAS

e BRAF e análise de MSI nas lesões precursoras do câncer colorretal. Hospital de Câncer de

Barretos, 2013.

5. Fregnani JH. Emilze Mafra de Lima. Saúde oral como fator de risco para neutropenia febril

pós quimioterapia em pacientes com neoplasias hematológicas. Fundação Pio XII - Hospital

de Câncer de Barretos, 2013.

6. Fregnani JH. Fernando Luís Visoni Poliseli. Avaliação do número de cópias do gene

TOP2A e da expressão da sua proteína em leiomiossarcomas uterinos. Hospital A.C.

Camargo, 2013.

7. Garcia EA. Maíra Degiovani Stein. Desempenho diagnóstico da citologia cervical

preparada em base líquida, lida manualmente versus a lida de forma automatizada e assistida

por computador. Hospital de Câncer de Barretos, 2013.

8. Garcia EA. Luana Pimenta Gomes. Avaliação dos fatores de crescimento endotelial

vascular VEGF e de seus principais receptores VEGFR-1 e -2 no processo de cicatrização

com influência da radioterapia em ratos da linhagem Wistar. Faculdade de Medicina da

Universidade de São Paulo, 2013.

9. Guimarães DP. Ana Laura Rodrigue Bordinhão. Avaliação da expressão de micrornas em

linhagens celulares de carcinoma mamário humano expostas a ação do fármaco Cediranib.

Hospital de Câncer de Barretos, 2013.

10. Longatto AF. Carlos Eduardo Mattos da Cunha Andrade. HPV-16 Como fator preditivo

de recorrência para lesões intraepiteliais do colo uterino tratadas cirurgicamente, Hospital de

Câncer de Barretos, 2013.

11. Lopes LF. Juliana Levy Daher. Análise da qualidade de vida, voz e deglutição no paciente

com câncer de cabeça e pescoço pré e pós tratamento oncológico, Hospital de Câncer de

Barretos, 2013.

12. Palmero EI. Croider Franco Lacerda. Perfil multinacional do gene supressor tumoral TP53

no carcinoma de células escamosas de esôfago associado ao megaesôfogo chagásico, Hospital

de Câncer de Barretos, 2013.

13. Palmero EI. Henrique de Campos Reis Galvão. Caracterização de pacientes com Polipose

Adenomatosa Familial atendidos no Hospital de Clínicas de Porto Alegre: enfoque nos

achados extracolônicos. Universidade Federal do Rio Grande do Sul. 2013.


14. Pinheiro C. Ana Laura Rodrigues Bordinhão. Avaliação da expressão de mircroRNAs em

linhagem celulares de carcinoma mamário humano expostas a ação do fármaco Cediranib”,

Hospital de Câncer de Barretos, 2013.

15. Reis RM. Thalles Olivi de Almeida. Valor do spect mibi cerebrla na predição da

sobrevida em pacientes portadores de glioblastoma multiforme. Hospital de Câncer de

Barretos, 2013.

16. Scapulatempo CN. Augusto Ludvik Filip Marino. Análise do perfil de expressão

diferencial de micrornas em carcinomas mamários por microarrays, Hospital de Câncer de

Barretos, 2013.

17. Marques MMC. Flávia Coltri Eguchi. Avaliação da superexpressãoda proteina ERG e da

fusão gênica- TMPRSS2: ERG em portadores de câncer prostático, Hospital de Câncer de

Barretos, 2013.

18. Marques MM. Thais Cristine Arns. Identificação de cascatas gênicas com base na

modulação trasncricional de células sangüíneas mononucleares periféricas de pacientes com

diabete mellitus do tipo 1”, Dissertação Mestrado, Faculdade de Medicina de Ribeirão Preto-

USP, Ribeirão Preto, 2013.

19. Vazquez VL. Regina Célia da Silva. Qualidade de vida em pacientes com linfoma não

Hodgkin durante a quimioterapia em regime ambulatorial: Avaliação com o questionário

EORTC-QLQ-C30. Hospital de Câncer de Barretos, 2013.

20. Vidal DO. Bruna Rodrigues Muys. Caracterização da estrutura e regulação dos genes

MGC16121 e CR596471. 2013. Faculdade de Medicina de Ribeirão Preto – USP, 2013.

16) National and Internacional Collaborations:

16.1 National

- Centro Internacional de Pesquisa e Ensino (CIPE) - Hospital AC Camargo, S. Paulo.

- Faculdade de Medicina da Universidade de São Paulo, S. Paulo.

- INCT-HPV, S. Paulo.

- Instituto de Medicina Integral Professor Fernando Figueira/ Instituto Materno Infantil de

Pernambuco (IMIP), Recife, PE.

- Laboratório de Poluição Atmosférica da Faculdade de Medicina da USP.

- Universidade Federal de Goiás.

- Universidade Federal do Rio Grande do Sul, Porto Alegre

16.2 International


- Harvard School of Public Health - HSPH, Boston, USA.

- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP),

Porto, Portugal.

- Life and Health Science Research Institute (ICVS), University of Minho, Braga, Portugal.

- MDAnderson Cancer Center, Houston, USA.

- The Institute of Cancer Research (ICR), Sutton, UK.

- St. Jude Children’s Research Hospital, Memphis, TN, USA.

17) Molecular Diagnostic Center

The Molecular Diagnostics Center (http://hcbdiagnostico.com.br/) is offering to the Barretos

Cancer Hospital patients and external Institutions a variety of tests currently used in the

clinical routine in the following áreas: Cytogenetics, Personalized Medicine and Oncogenetics.

18) Prespectives for 2014

- Increase the number of publications and projects by researcher;

- Consolidate and structure the research lines and increased the interaction among researchers;

- Fostering and increase adherence to Journals Club/Scientific Meetings and Meeting of

seniors/junior researchers;

- Animal house facility;

- Consolidate partnerships with national and international partners (academic/industry).

http://www.hsph.harvard.edu/

http://hcbdiagnostico.com.br/


MOLECULAR ONCOLOGY RESEARCH CENTER TEAM

2013 annual report - hospital de câncer de barretos 2013_cpom.pdf2013 annual report molecular...

Documents